Trial
NCT04041674
Evaluating the Safety and Immunogenicity of a Prime-boost Vaccine Regimen of GEO-D02 DNA and MVA/HIV62B With and Without B63521^11 gp120 and IHV01 gp120 Env Proteins in Healthy, HIV-uninfected Adult Participants
Phase IWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators
HIV Vaccine Trials Network (HVTN), Fred Hutch / University of Washington; GeoVax Labs, Inc; Duke University; University of Maryland, Baltimore
Condition
HIV Infections
Intervention
GEO-D02 DNA
Why stopped
Protocol undergoing additional revisions.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-10-15